FULL DISCLOSURE: This content is sponsored by PharmaDrug Inc.
PharmaDrug (CSE: PHRX) has formally engaged a research lab to refine and advance the development of its patented cocaine synthesis process.
The lab, Chiral Logistics Corp, is based in Victoria, BC, where it specializes in chemical synthesis, bio-synthesis, extractions, and isolations of active chemical substances. The research and development lab focuses on operating on a contractual basis to drive innovation in the pharma and biotech sectors.
The processes developed by the lab will remain as the wholly owned IP of SecureDose, the wholly-owned subsidiary of PharmaDrug that currently holds the IP on the novel cocaine synthesis method.
WATCH: PharmaDrug: A Path To Safe Supply
“We are extremely excited to begin working with Chiral Labs. The work will focus on both fine tuning the process and producing a test batch to prove out our method and formulation. We will also seek to partner with a licensed contract commercial manufacturer to collaborate on tactical commercial methods with a goal to begin producing a larger commercial batch early next year,” commented CEO Robert Steen.
PharmaDrug last traded at $0.035 on the CSE.
FULL DISCLOSURE: PharmaDrug is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of PharmaDrug. The author has been compensated to cover PharmaDrug on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
